Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Stuart M. Flechner, MD, is Director of Clinical Research in the Section of Renal Transplantation at Cleveland Clinic, and a Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio.
Dr. Flechner received a BA in zoology and his MD from the University of California at Los Angeles. After completing a residency in surgery and urology at Moffitt Hospital of the University of California, San Francisco, he did a fellowship in transplantation and renal vascular surgery at Cleveland Clinic.
Dr. Flechner has held academic appointments in the Division of Organ Transplantation at the University of Texas Medical School, Houston, and in the Division of Transplantation at Stanford University School of Medicine. His academic interests include the medical and surgical management of renal transplant recipients, transplant biology and the development and application of new and innovative immunosuppressive agents. He has recently completed a sabbatical at Scripps Research Institute in California in the Department of Molecular and Experimental Medicine. He is an Associate Editor of the Journal Clinical Transplantation.
Dr. Flechner has authored more than 225 scientific articles, chapters and reviews, and is a member of the Editorial Board of Transplantation. He is also an ad hoc reviewer for 18 scientific journals in the fields of transplantation, surgery and urology. Current projects include the development of calcineurin-free immunosuppressive regimens and signature patterns of gene expression in transplanted kidneys in various stages of function.
Kidney (renal) transplantation, kidney cancer, renal failure, polycystic kidney disease, vascular disease, adrenal tumors, kidney cysts
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Flechner's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.